The US Court of Appeals for the District of Columbia concluded Novartis AG and United Therapeutics Corporation did not violate the 340B outpatient drug discount program law by imposing restrictions on pharmacies dispensing drugs under contract with hospitals and other health care providers participating in the program.
340B Contract Pharmacy Confusion: Another US Court Sides With Pharma, States Enact Roadblocks
The DC Circuit Court agrees with an earlier appeals court ruling that the law does not prohibit manufacturers from setting the terms of their 340B outpatient drug discounts to contract pharmacies.
More from Legal & IP
More from Pink Sheet
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
• By
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."